← FDA DRUG APPROVALS

FDA ANDA · ANDA078745

RAMIPRIL

Sponsor: CHARTWELL MOLECULAR

APPLICATION
ANDA078745
TYPE
ANDA
ORIGINAL APPROVAL
2008-06-18
LATEST ACTION
2020-07-24
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription

Products

RAMIPRILPrescription
RAMIPRIL 5MG · CAPSULE · ORAL
RAMIPRILPrescription
RAMIPRIL 1.25MG · CAPSULE · ORAL
RAMIPRILPrescription
RAMIPRIL 10MG · CAPSULE · ORAL
RAMIPRILPrescription
RAMIPRIL 2.5MG · CAPSULE · ORAL

Approval history

2020-07-24Labeling · Supplement 11 · standardAP
2016-02-28Labeling · Supplement 9 · standardAP
2016-02-28Labeling · Supplement 8 · standardAP
2014-09-26Labeling · Supplement 7 · standardAP
2014-09-26Labeling · Supplement 5 · standardAP
2014-09-26Labeling · Supplement 3AP
2011-05-19Labeling · Supplement 2AP
2009-10-22Labeling · Supplement 1AP
2008-06-18OriginalOther Important Information from FDAAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →